Moonwalk Biosciences Raises $70 Million in Series B Funding
Moonwalk Biosciences, a San Francisco-based biotech company, has successfully raised $70 million in a Series B funding round. The investment, announced on September 8, 2026, was co-led by Alpha Wave and YK Bioventures. Other participants in the round included notable investors such as Eli Lilly, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures, and Future Ventures.
Moonwalk Biosciences is focused on a novel approach to therapy development by deeply profiling and targeting the epigenetic code. Their goal is to reprogram cells back to a healthy state, thereby transforming the way therapies are discovered and developed.
Leadership and Vision
The company was co-founded by a team of experts including Alex Aravanis MD PhD, who serves as the Chief Executive Officer, Arash Jamshidi, the President and CTO, and Justin Valley, the Chief Platform Officer. Together, they lead the company's mission to innovate within the biotech industry.
Use of Funds
While specific plans for the newly acquired funds were not disclosed, it is anticipated that the capital will be utilized to advance Moonwalk's research and development efforts, expand its team, and possibly explore new market opportunities.
Investor Interest
The participation of prominent investors such as Eli Lilly and Khosla Ventures underscores the strong interest in Moonwalk's potential to revolutionize therapeutic development through its unique approach to cell reprogramming.
Moonwalk Biosciences continues to make strides in the biotech sector, bolstered by this significant Series B funding, as it seeks to further its research and impact in transforming cell therapies.